NPS Pharmaceuticals (NPSP) 45.97 $NPSP
Shire to buy Baxalta for around $32 billion
M2 - Tue Jan 12, 6:03AM CST
"The target Baxalta and the orphan disease market are very compelling. The market is very attractive; worth $100+ Billion and has a CAGR of12 percent, almost twice of the general drugs market. Of the top 10 projected best-selling drugs world-wide in 2015, almost seven bear the orphan status. Additionally, the market has had favorable regulatory environment, having witnessed a record year for FDA/EU/Japan orphan designations in 2014."
NPSP: 45.97 (+0.01)
Progenics Pharmaceuticals Announces the Appointment of Patrick Fabbio as Chief Financial Officer
GlobeNewswire - Mon Nov 16, 6:30AM CST
Progenics Pharmaceuticals, Inc. (Nasdaq
GNX) today announced appointment of Patrick Fabbio as Chief Financial Officer. Mr. Fabbio, the former Vice President, Global Corporate Finance at NPS Pharmaceuticals, Inc., has over 20 years of financial experience in the healthcare sector at both publicly-traded and privately-held companies.
PGNX: 5.96 (-0.18), NPSP: 45.97 (+0.01)
Global Biosimilars Market Report, 2015-2025 - The biosimilar market is projected to be worth USD 32 billion worldwide by 2025
PR Newswire Europe - Tue Nov 03, 11:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/hcv3cc/global [http://www.researchandmarkets.com/research/hcv3cc/global]) has announced the addition of the "Global Biosimilars Market, 2015 - 2025" [http://www.researchandmarkets.com/research/hcv3cc/global] report to their offering.
BIIB: 313.59 (+7.56), UTHR: 122.91 (-0.30), CTIC: 0.39 (unch), CHRS: 30.81 (+0.83), JNJ: 119.32 (+0.24), NPSP: 45.97 (+0.01), IBIO: 0.59 (-0.02), EBS: 26.90 (+0.49), SLXP: 172.96 (+0.15), AMGN: 169.77 (-0.36), SPPI: 5.24 (-0.05), LLY: 76.85 (-0.38), GSK: 44.26 (+1.28), ANIK: 47.89 (-0.05), NVO: 45.80 (-0.54), BAX: 46.28 (+0.10), MRK: 62.98 (+0.08), NVS: 79.38 (+1.11)
Shire offers to buy Baxter drug spinoff for $30 billion
AP - Tue Aug 04, 3:29PM CDT
NEW YORK (AP) — The Irish drugmaker Shire is offering to buy Baxalta for about $30 billion in stock as it attempts to solidify its strengthening position in rare disease treatments.
BAX: 46.28 (+0.10), SHPG: 192.37 (+3.87), NPSP: 45.97 (+0.01), BXLT: 46.02 (-0.18)
Uptrend Call Working As NPS Pharmaceuticals Stock Rises 63.6% (NPSP)
Comtex SmarTrend(R) - Mon Apr 20, 11:12AM CDT
SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 6 months, NPS Pharmaceuticals has returned 63.62% as of today's recent price of $45.97.
NPSP: 45.97 (+0.01)
63.6% Return Seen to Date on SmarTrend NPS Pharmaceuticals Call (NPSP)
Comtex SmarTrend(R) - Mon Apr 13, 10:06AM CDT
SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 6 months, NPS Pharmaceuticals has returned 63.62% as of today's recent price of $45.97.
NPSP: 45.97 (+0.01)
NPS Pharmaceuticals Shares Up 63.6% Since SmarTrend's Buy Recommendation (NPSP)
Comtex SmarTrend(R) - Mon Apr 06, 9:18AM CDT
SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 6 months, NPS Pharmaceuticals has returned 63.62% as of today's recent price of $45.97.
NPSP: 45.97 (+0.01)
Shares of NPSP Up 63.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Mar 26, 4:47PM CDT
SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 5 months, NPS Pharmaceuticals has returned 63.62% as of today's recent price of $45.97.
NPSP: 45.97 (+0.01)
NPS Pharmaceuticals Has Returned 63.6% Since SmarTrend Recommendation (NPSP)
Comtex SmarTrend(R) - Thu Mar 19, 11:16AM CDT
SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 5 months, NPS Pharmaceuticals has returned 63.62% as of today's recent price of $45.97.
NPSP: 45.97 (+0.01)
Cynapsus Therapeutics Appoints Tamar Howson to Board of Directors
BusinessWire - Thu Mar 12, 3:10PM CDT
Cynapsus Therapeutics Inc. (TSX:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company focused on the treatment of OFF episodes in Parkinson's disease, today announced that Tamar Howson has been appointed to the Company's Board of Directors. With the addition of Ms. Howson to the Board of Directors, the Company now has eight directors, with seven directors classified as independent.
OXGN: 0.70 (-0.03), NPSP: 45.97 (+0.01), BMY: 56.35 (-0.41), CTH.TO: 51.58 (-0.40)
Will NPS Pharmaceuticals (NPSP) Miss on Earnings in Q4? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 16, 12:00PM CST
NPS Pharmaceuticals (NPSP), which is expected to report fourth-quarter 2014 results on Feb 17, had posted a negative earnings surprise of 300% in the last quarter.
ACT: 298.98 (-2.94), SHPG: 192.37 (+3.87), NPSP: 45.97 (+0.01), ARIA: 10.12 (-0.07)
Shire to buy Baxalta for around $32 billion
M2 - Tue Jan 12, 6:03AM CST
"The target Baxalta and the orphan disease market are very compelling. The market is very attractive; worth $100+ Billion and has a CAGR of12 percent, almost twice of the general drugs market. Of the top 10 projected best-selling drugs world-wide in 2015, almost seven bear the orphan status. Additionally, the market has had favorable regulatory environment, having witnessed a record year for FDA/EU/Japan orphan designations in 2014."
NPSP: 45.97 (+0.01)
Progenics Pharmaceuticals Announces the Appointment of Patrick Fabbio as Chief Financial Officer
GlobeNewswire - Mon Nov 16, 6:30AM CST
Progenics Pharmaceuticals, Inc. (Nasdaq
GNX) today announced appointment of Patrick Fabbio as Chief Financial Officer. Mr. Fabbio, the former Vice President, Global Corporate Finance at NPS Pharmaceuticals, Inc., has over 20 years of financial experience in the healthcare sector at both publicly-traded and privately-held companies. PGNX: 5.96 (-0.18), NPSP: 45.97 (+0.01)
Global Biosimilars Market Report, 2015-2025 - The biosimilar market is projected to be worth USD 32 billion worldwide by 2025
PR Newswire Europe - Tue Nov 03, 11:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/hcv3cc/global [http://www.researchandmarkets.com/research/hcv3cc/global]) has announced the addition of the "Global Biosimilars Market, 2015 - 2025" [http://www.researchandmarkets.com/research/hcv3cc/global] report to their offering.
BIIB: 313.59 (+7.56), UTHR: 122.91 (-0.30), CTIC: 0.39 (unch), CHRS: 30.81 (+0.83), JNJ: 119.32 (+0.24), NPSP: 45.97 (+0.01), IBIO: 0.59 (-0.02), EBS: 26.90 (+0.49), SLXP: 172.96 (+0.15), AMGN: 169.77 (-0.36), SPPI: 5.24 (-0.05), LLY: 76.85 (-0.38), GSK: 44.26 (+1.28), ANIK: 47.89 (-0.05), NVO: 45.80 (-0.54), BAX: 46.28 (+0.10), MRK: 62.98 (+0.08), NVS: 79.38 (+1.11)
Shire offers to buy Baxter drug spinoff for $30 billion
AP - Tue Aug 04, 3:29PM CDT
NEW YORK (AP) — The Irish drugmaker Shire is offering to buy Baxalta for about $30 billion in stock as it attempts to solidify its strengthening position in rare disease treatments.
BAX: 46.28 (+0.10), SHPG: 192.37 (+3.87), NPSP: 45.97 (+0.01), BXLT: 46.02 (-0.18)
Uptrend Call Working As NPS Pharmaceuticals Stock Rises 63.6% (NPSP)
Comtex SmarTrend(R) - Mon Apr 20, 11:12AM CDT
SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 6 months, NPS Pharmaceuticals has returned 63.62% as of today's recent price of $45.97.
NPSP: 45.97 (+0.01)
63.6% Return Seen to Date on SmarTrend NPS Pharmaceuticals Call (NPSP)
Comtex SmarTrend(R) - Mon Apr 13, 10:06AM CDT
SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 6 months, NPS Pharmaceuticals has returned 63.62% as of today's recent price of $45.97.
NPSP: 45.97 (+0.01)
NPS Pharmaceuticals Shares Up 63.6% Since SmarTrend's Buy Recommendation (NPSP)
Comtex SmarTrend(R) - Mon Apr 06, 9:18AM CDT
SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 6 months, NPS Pharmaceuticals has returned 63.62% as of today's recent price of $45.97.
NPSP: 45.97 (+0.01)
Shares of NPSP Up 63.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Mar 26, 4:47PM CDT
SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 5 months, NPS Pharmaceuticals has returned 63.62% as of today's recent price of $45.97.
NPSP: 45.97 (+0.01)
NPS Pharmaceuticals Has Returned 63.6% Since SmarTrend Recommendation (NPSP)
Comtex SmarTrend(R) - Thu Mar 19, 11:16AM CDT
SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 5 months, NPS Pharmaceuticals has returned 63.62% as of today's recent price of $45.97.
NPSP: 45.97 (+0.01)
Cynapsus Therapeutics Appoints Tamar Howson to Board of Directors
BusinessWire - Thu Mar 12, 3:10PM CDT
Cynapsus Therapeutics Inc. (TSX:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company focused on the treatment of OFF episodes in Parkinson's disease, today announced that Tamar Howson has been appointed to the Company's Board of Directors. With the addition of Ms. Howson to the Board of Directors, the Company now has eight directors, with seven directors classified as independent.
OXGN: 0.70 (-0.03), NPSP: 45.97 (+0.01), BMY: 56.35 (-0.41), CTH.TO: 51.58 (-0.40)
Will NPS Pharmaceuticals (NPSP) Miss on Earnings in Q4? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 16, 12:00PM CST
NPS Pharmaceuticals (NPSP), which is expected to report fourth-quarter 2014 results on Feb 17, had posted a negative earnings surprise of 300% in the last quarter.
ACT: 298.98 (-2.94), SHPG: 192.37 (+3.87), NPSP: 45.97 (+0.01), ARIA: 10.12 (-0.07)
